Cadherin
Cadherins are a family of calcium-dependent cell adhesion molecules and transmembrane glycoproteins that play a crucial role in maintaining tissue architecture and cellular communication. Key members of the cadherin family include E-cadherin (CDH1), N-cadherin (CDH2), and P-cadherin (CDH3), etc. Cadherins mediate cell-cell adhesion through homophilic interactions, forming adherens junctions that connect to the actin cytoskeleton via catenins, thus influencing cellular signaling pathways related to proliferation, differentiation, and migration[1].
cadherins are involved in various signaling pathways, such as the Wnt and Notch pathways, which are critical for development and tissue homeostasis. Cadherins often bind to β-catenin (CTNNB1) through the catenin-binding domain. The catenin-binding domain of cadherin is crucial in cadherin function and it plays an important role in maintaining epithelial integrity. Dysregulation of cadherin expression is associated with several diseases, particularly cancer, such as pancreatic cancer, melanoma, hepatocellular carcinoma, glioblastoma, breast and gastric cancers. The epigenetic silencing of cadherins through mechanisms like DNA methylation further exacerbates this issue in tumor progression. Understanding cadherins' roles in cellular dynamics provides insights into potential therapeutic targets for cancer and other diseases characterized by altered cell adhesion[1].
cadherins are involved in various signaling pathways, such as the Wnt and Notch pathways, which are critical for development and tissue homeostasis. Cadherins often bind to β-catenin (CTNNB1) through the catenin-binding domain. The catenin-binding domain of cadherin is crucial in cadherin function and it plays an important role in maintaining epithelial integrity. Dysregulation of cadherin expression is associated with several diseases, particularly cancer, such as pancreatic cancer, melanoma, hepatocellular carcinoma, glioblastoma, breast and gastric cancers. The epigenetic silencing of cadherins through mechanisms like DNA methylation further exacerbates this issue in tumor progression. Understanding cadherins' roles in cellular dynamics provides insights into potential therapeutic targets for cancer and other diseases characterized by altered cell adhesion[1].
All Product Categories
-
Cadherin Related Products (62)
Related Products (62)
-
Sorafenib
0 ImagesSynonyms: Bay 43-9006Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Sorafenib tosylate
0 ImagesSynonyms: Bay 43-9006 tosylateSorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
ADH-1
0 ImagesADH-1, an N-cadherin antagonist, inhibits N-cadherin mediated cell adhesion.
-
Rentosertib
0 ImagesSynonyms: INS018_055; TNIK&MAP4K4-IN-2Rentosertib (INS018 055) (compound 112) is the orally active TNIK and MAP4K4 inhibitor with IC50 values of 12-120, 12-120 nM, respectively.
-
THR-123 TFA
0 ImagesCat. No.: HY-P11354ATHR-123 TFA is an orally active ALK3 peptide agonist. THR-123 TFA has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 TFA suppresses inflammation, Apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 TFA can be used for the study of kidney fibrosis.
-
Ligusticum cycloprolactam
0 ImagesCat. No.: HY-N17383CAS No.: 2283387-37-9Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease.
-
NUAK1-IN-3
0 ImagesCat. No.: HY-182361CAS No.: 3097515-05-1NUAK1-IN-3 is a potent and selective NUAK1 inhibitor with an IC50 of 0.49 nM. NUAK1-IN-3 also inhibits NUAK2 and JAK3 with IC50 values of 265 and 225 nM. NUAK1-IN-3 engages Glu139 of NUAK1, forms a salt bridge between its bicyclic ring nitrogen and Asp142, and uses a fluorine atom to enhance hydrophobic binding interactions. NUAK1-IN-3 attenuates MYPT1 phosphorylation, suppresses the NUAK1-MYPT1 signaling axis, and inhibits proliferation, migration, and invasion of triple-negative breast cancer cells. NUAK1-IN-3 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT) marker alterations, downregulates Snail and N-cadherin, and upregulates E-cadherin in tumor tissues. NUAK1-IN-3 suppresses tumor growth in triple-negative breast cancer xenograft models. NUAK1-IN-3 can be used for the research of triple-negative breast cancer.
-
Tralokinumab
0 ImagesSynonyms: CAT354
-
Anti-CDH17/Cadherin-17 Antibody (PTA001_A4)
0 ImagesCat. No.: HY-P990363Purity: 99.28%Synonyms: PTA001_A4The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHO cells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
-
Vasculotide
0 ImagesVasculotide is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury.
-
Anti-CDH17/Cadherin-17 Antibody (10C12)
0 ImagesCat. No.: HY-P991100Purity: 99.29%
-
MC-1-F2
0 ImagesMC-1-F2 is a FOXC2 inhibitor. MC-1-F2 shows a binding affinity (Kd) of 26 μM for full-length FOXC2. MC-1-F2 reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. MC-1-F2 can be used for the study of CRPC and breast cancer.
-
Vasculotide TFA
0 ImagesCat. No.: HY-P10580APurity: 99.88%Vasculotide TFA is a blood-brain barrier (BBB)-penetrant Tie2 agonist. Vasculotide TFA binds to a unique domain of Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability. Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury.
-
Aristolactam I
0 ImagesSynonyms: Aristololactam; AristolactamAristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
-
ADH-1 trifluoroacetate
0 ImagesADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.
-
N-Feruloyloctopamine
0 ImagesSynonyms: N-trans-FeruloyloctopamineN-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma.
-
E-Cadherin activator-1
0 ImagesE-cadherin activator-1 (Compound 13m) is an E-Cadherin activator. E-cadherin activator-1 can be used in the study of colorectal carcinoma.
